Related Experiment Videos
Biomarkers in COPD
Eleni G Tzortzaki1, Irini Lambiri, Eleni Vlachaki
1Department of Thoracic Medicine, University of Crete, Medical School, Heraklion, Crete, Greece.
Current Medicinal Chemistry
|April 19, 2007
Summary
Chronic Obstructive Pulmonary Disease (COPD) involves lung inflammation and systemic effects, driven by various molecular factors. Identifying reliable biomarkers in samples like sputum and blood is crucial for understanding COPD progression and developing new treatments.
Area of Science:
- Pulmonary Medicine
- Biomarker Discovery
- Molecular Pathogenesis
Background:
- Chronic Obstructive Pulmonary Disease (COPD) is an abnormal inflammatory lung response to harmful inhaled substances, primarily cigarette smoke.
- COPD has significant systemic consequences beyond the lungs, involving inflammation, oxidative stress, and genetic factors.
- Pathogenesis involves complex cellular and molecular events driven by enzymes, cytokines, chemokines, and growth factors.
Purpose of the Study:
- To review recent findings on potential pulmonary biomarkers for Chronic Obstructive Pulmonary Disease (COPD).
- To highlight the importance of biomarkers for understanding COPD natural history and treatment development.
- To explore biomarkers across various biological samples relevant to COPD.
Main Methods:
- Review of current scientific literature on COPD pathobiology and biomarkers.
- Analysis of potential biomarkers found in induced sputum, exhaled air condensate, peripheral blood, urine, bronchoalveolar lavage fluid, and bronchial biopsies.
- Evaluation of cellular and molecular events contributing to COPD pathogenesis.
Main Results:
- Numerous biomarkers have been evaluated in COPD, often showing redundancy.
- Despite redundancy, specific biomarkers show promise for indicating lung damage, inflammation, and systemic disease.
- Potential biomarkers are identified across diverse sample types, offering various detection possibilities.
Conclusions:
- Developing relevant biomarkers for lung damage, pulmonary inflammation, and systemic disease is essential for advancing COPD understanding.
- Biomarker discovery is key to improving the natural history insights and therapeutic strategies for COPD.
- Further research into validated biomarkers across multiple sample types will aid in effective COPD management.
Related Concept Videos
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...